ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly rest of World / Other foreign countries revenue ($M) ($M)
Form 10-Q / 10-K Geographic Information Note
Latest, Q2 2026
2,877
Period ended Jun 30, 2026
Change on a year earlier
+143.4%
1,182 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rest of World / Other foreign countries revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 2,877 | +143.4% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,771 | +177.9% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 2,190 | +105.8% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,688 | +52.3% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,182 | -2.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 997 | +11.7% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,064 | +43.0% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,108 | +42.0% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,206 | +61.1% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 893 | +32.7% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 744 | -9.6% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2023 | Sep 30, 2023 | 780 | +23.5% | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 749 | +15.9% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 673 | -10.4% | Form 10-Q (filed 2024-04-30) ↗ |
| Q4 2022 | Dec 31, 2022 | 823 | +7.5% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 632 | -8.3% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 646 | +1.2% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 752 | +23.4% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 766 | +17.0% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 689 | +18.2% | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 638 | +10.9% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 609 | -0.2% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 654 | +2.3% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 583 | -0.7% | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 575 | +0.6% | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 610 | +11.8% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 639 | +2,542.1% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 587 | -22.4% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 572 | -24.9% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 546 | -28.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 24.2 | -80.7% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 757 | -17.7% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 761 | -16.3% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 767 | -12.3% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 125 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 920 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 909 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 875 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Rest of World / Other foreign countries revenue ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rev_geo_row
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.